A
ALX Oncology Holdings Inc. (ALXO)
NMS – Real Time Price. Currency in USD
2.04
0.00 (0.00%)
At close: Mar 27, 2026, 4:00 PM EDT
1.99
-0.05 (-2.45%)
After-hours: Mar 27, 2026, 4:47 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
2.04
0.00 (0.00%)
At close: Mar 27, 2026, 4:00 PM EDT
1.99
-0.05 (-2.45%)
After-hours: Mar 27, 2026, 4:47 PM EDT
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. Athanasios Tsiatis M.D. | Senior Vice President of Clinical Development |
| Dr. Barbara J. Klencke M.D. | Chief Medical Officer |
| Dr. Lin Yeong-Liang M.D., M.S. | Senior Vice President of Drug Safety & Pharmacovigilance |
| Mr. Harish Shantharam C.F.A. | Chief Financial Officer |
| Mr. Jason W. Lettmann | CEO & Director |
| Ms. Lisa Sauer | Senior Vice President of Regulatory Affairs & Quality Assurance |
| Ms. Shelly Pinto CPA | Senior VP of Finance & Chief Accounting Officer |
| Ms. Sue Naim | Senior Vice President of Clinical Operations |
| Ms. Venita De Almeida Ph.D. | VP & Head of Research Program Development |
| Date | Type | Document |
|---|---|---|
| 2026-03-09 | 10-K | alxo-20251231.htm |
| 2026-01-21 | S-8 | alxo-20260121.htm |
| 2025-11-07 | 8-K | alxo-20251107.htm |
| 2025-09-12 | 8-K | alxo-20250911.htm |
| 2025-08-12 | 8-K | alxo-20250812.htm |
| 2025-06-12 | 8-K | alxo-20250611.htm |
| 2025-05-08 | 8-K | alxo-20250508.htm |
| 2025-04-25 | 8-K | alxo-20250423.htm |
| 2025-04-21 | DEF 14A | alxo-20250421.htm |
| 2025-03-06 | 8-K | alxo-20250306.htm |